EC approves Sanofi's Lyxumia

The European Commission approved an MAA for Lyxumia lixisenatide from Sanofi (Euronext:SAN; NYSE:SNY) to improve glycemic control in adult Type II diabetics. The pharma, which submitted an NDA to FDA for the glucagon-like peptide-1 receptor ( GLP-1R) agonist in late 2012, said it plans to launch Lyxumia in the U.K. and Germany this half. ...